1,732,571 Shares in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Bought by Boxer Capital Management LLC

Boxer Capital Management LLC bought a new stake in shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 1,732,571 shares of the company's stock, valued at approximately $13,982,000. ORIC Pharmaceuticals makes up approximately 1.2% of Boxer Capital Management LLC's holdings, making the stock its 25th biggest holding. Boxer Capital Management LLC owned 2.46% of ORIC Pharmaceuticals at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Barclays PLC raised its position in ORIC Pharmaceuticals by 111.2% during the third quarter. Barclays PLC now owns 107,261 shares of the company's stock valued at $1,100,000 after purchasing an additional 56,474 shares during the period. Franklin Resources Inc. increased its position in shares of ORIC Pharmaceuticals by 26.1% during the 3rd quarter. Franklin Resources Inc. now owns 950,459 shares of the company's stock valued at $9,067,000 after purchasing an additional 196,804 shares during the last quarter. JPMorgan Chase & Co. raised its holdings in ORIC Pharmaceuticals by 3.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 35,251 shares of the company's stock valued at $361,000 after buying an additional 1,279 shares during the period. Hennion & Walsh Asset Management Inc. lifted its position in ORIC Pharmaceuticals by 18.1% in the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 162,909 shares of the company's stock worth $1,315,000 after buying an additional 24,947 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. boosted its stake in ORIC Pharmaceuticals by 10.3% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 14,963 shares of the company's stock worth $121,000 after buying an additional 1,395 shares during the period. Institutional investors own 95.05% of the company's stock.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on ORIC shares. Oppenheimer lowered their target price on shares of ORIC Pharmaceuticals from $15.00 to $12.00 and set an "outperform" rating for the company in a report on Tuesday. Wedbush reaffirmed an "outperform" rating and set a $20.00 target price on shares of ORIC Pharmaceuticals in a research note on Thursday, March 20th. Guggenheim reissued a "buy" rating on shares of ORIC Pharmaceuticals in a research note on Wednesday, February 26th. HC Wainwright restated a "buy" rating and set a $21.00 price objective on shares of ORIC Pharmaceuticals in a report on Monday. Finally, JPMorgan Chase & Co. increased their target price on ORIC Pharmaceuticals from $21.00 to $22.00 and gave the stock an "overweight" rating in a research note on Wednesday, February 26th. Nine investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has a consensus rating of "Buy" and an average target price of $18.43.

ORIC Pharmaceuticals Stock Down 4.8 %

NASDAQ:ORIC traded down $0.24 during mid-day trading on Wednesday, reaching $4.80. The company's stock had a trading volume of 243,886 shares, compared to its average volume of 638,084. ORIC Pharmaceuticals, Inc. has a 1 year low of $3.90 and a 1 year high of $14.67. The stock has a fifty day moving average of $6.06 and a 200-day moving average of $8.15. The firm has a market capitalization of $340.92 million, a PE ratio of -2.64 and a beta of 1.37.

ORIC Pharmaceuticals (NASDAQ:ORIC - Get Free Report) last released its quarterly earnings data on Monday, May 5th. The company reported ($0.42) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.52) by $0.10. On average, analysts expect that ORIC Pharmaceuticals, Inc. will post -2.17 earnings per share for the current year.

ORIC Pharmaceuticals Company Profile

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.